PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
CONNECT2-EDO51 is a double-blind, placebo-controlled, multiple ascending dose Phase 2 trial designed to evaluate PGN-EDO51 at dose levels administered intravenously once every four weeks for 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback